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Abstract
Major depressive disorder (MDD) is associated with altered mineralocorticoid receptor (MR) and glucocorticoid
receptor function, and disturbed glutamatergic signaling. Both systems are closely intertwined and likely contribute
not only to the pathophysiology of MDD, but also to the increased cardiovascular risk in MDD patients. Less is known
about other steroid hormones, such as aldosterone and DHEA-S, and how they affect the glutamatergic system and
cardiovascular disease risk in MDD. We examined salivary cortisol, aldosterone, and DHEA-S secretion after stimulation
of MR and glutamatergic NMDA receptors in 116 unmedicated depressed patients, and 116 age- and sex-matched
healthy controls. Patients (mean age= 34.7 years, SD= ±13.3; 78% women) and controls were randomized to four
conditions: (a) control condition (placebo), (b) MR stimulation (0.4 mg fludrocortisone), (c) NMDA stimulation (250 mg
D-cycloserine (DCS)), and (d) combined MR/NMDA stimulation (fludrocortisone+ DCS). We additionally determined
the cardiovascular risk profile in both groups. DCS had no effect on steroid hormone secretion, while cortisol secretion
decreased in both fludrocortisone conditions across groups. Independent of condition, MDD patients showed (1)
increased cortisol, increased aldosterone, and decreased DHEA-S concentrations, and (2) increased glucose levels and
decreased high-density lipoprotein cholesterol levels compared with controls. Depressed patients show profound
alterations in several steroid hormone systems that are associated both with MDD pathophysiology and increased
cardiovascular risk. Prospective studies should examine whether modulating steroid hormone levels might reduce
psychopathology and cardiovascular risk in depressed patients.
Introduction
Stress is a risk factor for the development of major
depressive disorder (MDD)1 and cardiovascular disease
(CVD)2. Furthermore, stress activates the
hypothalamus–pituitary–adrenal (HPA) axis leading to the
release of the steroid hormone cortisol and consecutive
enhanced secretion of the neurotransmitter glutamate3. Both
systems are closely intertwined3,4, and altered secretion of
cortisol and glutamate is not only involved in the patho-
genesis of MDD5,6, but may also contribute to the increased
cardiovascular risk of depressed patients1,7–9. However, to
our knowledge, steroid hormone secretion after separate or
combined stimulation of the HPA axis, and glutamatergic
system in depressed patients and healthy controls has not
been studied so far.
Cortisol acts upon glucocorticoid receptors (GR) and
mineralocorticoid receptors (MR) in the central nervous
system. While GR are widely distributed in the brain, MR
are predominantly expressed in the hippocampus and
prefrontal cortex. MR are predominantly occupied during
basal cortisol secretion, whereas GR are increasingly
occupied as cortisol levels rise, for example, after stress.
Cortisol binding to GR and MR inhibits HPA axis activ-
ity1,10,11. In MDD, this negative feedback is impaired and
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cortisol levels increase12, possibly because of impaired MR
function13–15.
Elevated cortisol alters glutamate signaling in the hip-
pocampus and prefrontal cortex3. Not surprisingly, MDD
is associated with disturbed glutamatergic signaling. For
example, decreased levels of glutamatergic metabolites
have been reported in the medial frontal cortex of patients
with MDD6,16. Glutamate acts on metabotropic and
ionotropic receptors3, including the N-methyl-D-
aspartate (NMDA) receptor, which has been closely
implicated in the pathogenesis of MDD17. In fact, the U.S.
Food and Drug Administration18 recently approved the
rapid-acting NMDA receptor antagonist ketamine as a
treatment for treatment-resistant depression after its
efficacy was shown in several trials19. Importantly, keta-
mine strongly elevates cortisol levels20,21. However, the
glutamate system is extremely complex and there is evi-
dence that D-cycloserine (DCS), a partial agonist at the
glycine binding site of the NMDA receptor, exhibits
antidepressant effects22,23, and increases glutamate and
GABA in the brain to the same extent as ketamine24.
As well as contributing to the pathogenesis of MDD,
alterations in HPA activity and glutamate signaling may
also contribute to the elevated risk of CVD in depressed
patients7,25,26. Other steroid hormones, such as increased
aldosterone27,28 and decreased DHEA-S levels29, are also
closely linked to CVD. Importantly, increased aldosterone
levels30–32 and decreased DHEA-S concentrations33 have
been found in depressed patients, and both hormones
interact with the glutamate system34–36.
Taken together, the HPA axis and the glutamatergic
system play an important role in the pathogenesis of
depression and might represent an important link to
CVD. However, little is known about the interplay of both
systems in MDD. To address this, we examined (a) sali-
vary cortisol, aldosterone, and DHEA-S secretion after
stimulation of MR and glutamatergic NMDA receptors,
and (b) the cardiovascular risk profile in 116 unmedicated




In total, we examined 116 MDD patients and 116
healthy controls. We recruited patients from our in- and
outpatient clinics for affective disorders (Department of
Psychiatry and Psychotherapy of the Charité – Uni-
versitätsmedizin Berlin), via our website, and through
flyers distributed in outpatient psychiatric practices and
psychotherapy institutes. Healthy participants were
recruited via our website and through flyers distributed in
universities and other public spaces.
We matched depressed patients with healthy controls
based on sex, age, and education duration. For every
enrolled depressed patient, we recruited a control subject
who was matched on these characteristics. Inclusion cri-
teria were 18–65 years of age, a diagnosis of MDD
according to the fifth edition of the Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM-5)37, and a
score of 18 or more on the Hamilton rating scale for
depression (HAMD)38.
Exclusion criteria were intake of psychotropic medica-
tion during the last 5 days (except antidepressants as sleep
medication and benzodiazepines as needed), substance
abuse or dependency within the last 6 months, any cur-
rent episode or history of schizophrenia, schizoaffective,
or bipolar disorder (for healthy individuals, the presence
of any psychiatric disorders), neuroendocrine disorders,
current or past organic brain disease, acute suicidality,
endocrine disorders or intake of medication with neu-
roendocrine effects, pregnancy or lactation, unstable
cardiovascular conditions, known intolerance of study
medication, or significantly abnormal laboratory values.
All participants provided written informed consent and
received an expense allowance. The study was conducted
in accordance with the latest version of the Declaration of
Helsinki and was approved by the local ethics committee
(Landesamt für Gesundheit und Soziales Berlin, 16-0031-
EK 11).
Experimental design
We used a randomized double-blind placebo-controlled
parallel group design. The pharmacy of the Charité –
Universitätsmedizin Berlin conducted the block rando-
mization and blinded the medication. To stimulate MR,
we used 0.4 mg fludrocortisone. To stimulate NMDA
receptors, we used 250 mg DCS. In the control condition,
we administered placebo. Participants were randomly
assigned to one of the following four conditions: (a)
control condition (placebo+ placebo), (b) MR stimulation
only (fludrocortisone+ placebo), (c) NMDA stimulation
only (placebo+DCS), and (d) combined MR and NMDA
stimulation (fludrocortisone+DCS). Twenty-nine
depressed patients and 29 healthy controls took part in
each condition.
Procedure
Participants were assessed for eligibility by telephone
interview, and eligible participants were invited for the
formal screening visit. An experienced clinician (physician
or psychologist) from our team interviewed participants
to acquire demographic information and to diagnose or
exclude MDD according to DSM-5 criteria37. The HAMD
interview38 was also conducted and participants were
asked to complete the Beck Depression Inventory39 before
undergoing an electrocardiogram. To assess the cardio-
vascular risk profile, we measured blood pressure and
heart rate, and took blood samples for laboratory analyses.
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The experiment (separate or combined stimulation of MR
and NMDA receptors) took place at least 24 h and not
>7 days after the screening visit.
All experiments started at the same time (11:30 h) to
control for influences of the circadian rhythm on cortisol
secretion40. After arriving at the laboratory, participants
rested for 30min before the first blood pressure and heart
rate measurements were taken. Two baseline saliva sam-
ples were taken at 11:55 h and 12:00 h. From 12:00 h on,
we measured blood pressure and heart rate and took
saliva samples every hour until 18:00 h. Participants
received the first medication at 12:05 h and the second
medication at 13:05 h (Supplementary Fig. 1).
At three time points (prior to medication 11:50 h, dur-
ing the experiment 13:50 h, and at the end of the
experiment 17:50 h), we assessed the current mood state
of all participants with a visual analogue mood scale
(VAMS). We asked all participants to answer the question
“how are you currently feeling?” by making a cross on the
VAMS, which ranged from 0 (very bad) to 100
(very good).
Between measurements, participants were allowed to
walk around, read, or watch a movie. Participants were
allowed to drink water, but did not eat during the
experiment (11:30 h until 18:00 h). Ten minutes before
every measurement, participants were asked to rest, sit on
a chair, and stop drinking water. An experimenter was
present during the whole testing period. Participants
conducted cognitive tasks on a computer between 16:00 h
and 17:00 h for ~45min.
Cardiovascular risk assessment
The cardiovascular risk assessment took place at the
screening visit. We measured systolic and diastolic blood
pressure (mmHg), and heart rate (bpm) using the Boso
Medicus Uno (Bosch+ Sohn, Germany) apparatus as a
hemodynamometer. Blood samples were analyzed by the
Labor Berlin (Charité – Universitätsmedizin Berlin). We
measured total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cho-
lesterol, C-reactive protein (CRP), and glucose (all mea-
sured in mg/l or mg/dl respectively).
Steroid hormone measurement
We collected saliva samples with Code Blue Salivettes®
(Sarstedt, Germany) on the day of the experiment. Steroid
levels were analyzed in the neurobiological laboratory at
the Department of Psychiatry and Psychotherapy of the
Charité – Universitätsmedizin Berlin. For all salivary
analyses, we used enzyme-linked immunosorbent assays
(ELISA; IBL International GmbH, Germany). For cortisol
analyses (measured in nmol/L), an ELISA kit with a
detection limit of 0.08 nmol/L was used. For aldosterone
analyses (measured in pg/mL), we used an ELISA kit with
a detection limit of 12 pg/mL. DHEA-S levels (measured
in ng/mL) were measured using an ELISA kit optimized
for saliva with a detection limit of 0.05 ng/mL. The intra-
assay coefficients of variation were <8% and the inter-
assay coefficients of variation were <10% for all analyses.
To improve comparability, we converted all steroid hor-
mone measurement units into pg/mL for all figures.
Statistical analyses
Statistical analyses were conducted with IBM SPSS
Statistics (version 25). Greenhouse–Geisser corrections or
Welch tests were applied if assumptions of sphericity or
homogeneity of variances were violated. Post hoc analyses
were conducted with Bonferroni tests or contrasts if
applicable.
To analyze demographic variables, we used chi-squared
tests for categorical data and independent t-tests for
continuous data. If the assumptions of the chi-squared
test were violated, we used Fisher’s exact test. For cardi-
ovascular risk assessment (blood pressure, heart rate,
cholesterol, HDL cholesterol, LDL cholesterol, CRP, and
glucose), we used independent t-tests for group
comparisons.
Steroid hormone concentrations (cortisol, aldosterone,
and DHEA-S) were analyzed with mixed ANOVAs with
within-subject factor time (measurement time points),
between-subject factors group (depressed patients and
healthy controls), and condition (placebo, fludrocortisone,
DCS, and fludrocortisone+DCS).
All non-normally distributed data were log transformed.
Missing values for single cortisol and DHEA-S measure-
ment time points in four participants were replaced by
mean imputation (mean value of the preceding and sub-
sequent measurement time points) to avoid loss of data.
The current mood state was analyzed with mixed
ANOVAs with within-subject factor time (measurement
time points), between-subject factors group (depressed
patients and healthy controls), and condition (placebo,
fludrocortisone, DCS, and fludrocortisone+DCS).
We calculated correlations between the cardiovascular
risk assessment (blood pressure, heart rate, cholesterol,
HDL cholesterol, LDL cholesterol, CRP, and glucose)
measured at the screening visit and steroid hormone
secretion during the experiment. For the steroid hor-
mones cortisol, aldosterone, and DHEA-S, we calculated
area under the curve values with respect to the ground.
Sample size was calculated with G*Power41. Effect sizes
for condition effects were based on the fludrocortisone
effects on cortisol (η2= 0.12) reported in our earlier
study42. The effect size (η2= 0.10) for group (depressed
patients versus controls) were based on a meta-analysis on
differences in the cortisol response to stress between
depressed patients and controls43. Using mixed ANOVAs
with η2= 0.10, α= 0.05, and 1− β= 0.95, we calculated a
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total sample size of n= 120. To be able to find smaller
effects and considering possible dropouts, we con-
servatively recruited a larger sample of n= 232 partici-
pants: n= 116 per group, and n= 58 per condition.
Results
Sample characteristics
Depressed patients and healthy controls did not differ in
age, sex, education duration, or intake of hormonal con-
traceptives. There were more smokers among depressed
patients than among healthy controls (Table 1). There-
fore, we repeated the analyses in nonsmokers to examine
a possible confounding effect of smoking status. Addi-
tional analyses on sample and depression characteristics
with respect to condition are presented in the supplement
(Supplementary Tables 1 and 2).
Depressed patients took the following medication:
benzodiazepines as needed (n= 13), low-dose anti-
depressants as sleep medication (n= 5), cetirizine (n= 1),
pantoprazole (n= 1), ramipril (n= 3), lercanidipine (n= 1),
simvastatin (n= 2), rosuvastatin (n= 1), L-thyroxine
(n= 11), propylthiouracil (n= 1), dorzolamide (n= 1),
actaea racemosa (n= 1), sumatriptan (n= 1), amlodipine
(n= 2), indapamide (n= 1), valsartan (n= 1), and zopiclone
(n= 2). Healthy controls took the following medication:
salbutamole (n= 1), L-thyroxine (n= 10), tapentadol
(n= 1), mesalazine (n= 1), ramipril (n= 1), metoprolol
(n= 1), and estradiol (n= 1).
Steroid hormone response to separate or combined MR
and NMDA receptor stimulation
Cortisol
We found a main effect of group on cortisol levels
(F(1,222)= 4.0, p < 0.05, η2= 0.02), indicating that
depressed patients had higher cortisol concentrations
compared with healthy controls independent of
condition and time (Fig. 1a). In addition, we found a
main effect of condition (F(3,222)= 4.8, p < 0.01, η2=
0.06) and time (F(3,696)= 266.2, p < 0.001, η2= 0.55) on
cortisol concentrations, and an interaction between
condition × time (F(9,696)= 11.0, p < 0.001, η2= 0.13).
One-way ANOVAs with Bonferroni post hoc tests
revealed decreased cortisol secretion in both flu-
drocortisone conditions compared with the placebo and
DCS-only conditions (all p < 0.05; Fig. 1b, c). Analyses in
nonsmokers confirmed the results.
Aldosterone
We found a main effect of group on aldosterone levels
(F(1,222)= 10.2, p < 0.01, η2= 0.04), indicating that
depressed patients had higher aldosterone concentrations
compared with healthy controls independent of condition
and time (Fig. 2a). We found no main effect of condition
(p > 0.05; Fig. 2b, c) but a main effect of time (F(2,660)=
33.7, p < 0.001, η2= 0.13) on aldosterone levels, indicating
a decrease in aldosterone concentrations. Analyses in
nonsmokers confirmed the results.
DHEA-S
There was a main effect of group on DHEA-S con-
centrations (F(1,222)= 8.3, p < 0.01, η2= 0.04), indicating
that depressed patients had lower DHEA-S concentra-
tions compared with healthy controls independent of
condition and time (Fig. 3a). We found no main effect of
condition (p > 0.05; Fig. 3b, c) but a main effect of time
(F(3,704)= 12.3, p < 0.001, η2= 0.05) on DHEA-S con-
centrations. Analyses in nonsmokers revealed a slightly
reduced effect size for the main effect of group (F(1,179)
= 3.7, p= 0.056, η2= 0.02) and confirmed the time effect
(p < 0.001).
Table 1 Sample characteristics.
Healthy controls Depressed patients Statistics
n 116 116
Age, mean (SD) 34.9 (13.2) 34.7 (13.3) t(230)= 0.1, p= 0.90
Women, n (%) 91 (78%) 91 (78%)
Education years 12.1 (1.3) 11.8 (1.3) t(230)= 1.6, p= 0.12
BMI 23.5 (3.4) 24.0 (4.3) t(230)=−0.9, p= 0.36
Smoker 14 (12%) 30 (26%) χ²(1)= 7.2, p < 0.01
Hormonal contraception 19 (21%) 19 (21%)
HAMD 1.6 (1.3) 21.5 (3.4) t(149)=−58.7, p < 0.001
BDI 1.4 (1.8) 25.7 (8.3) t(125)=−30.8, p < 0.001
Values represent mean (SD) or n (%).
BMI body mass index, HAMD Hamilton ratings scale for depression, BDI Beck Depression Inventory.
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Blood pressure and heart rate
For systolic blood pressure, we found a main effect of
time (F(5,1150)= 43.6, p < 0.001, η2= 0.16) and a condi-
tion × time interaction (F(15,1150)= 2.4, p < 0.01, η2=
0.31), indicating an increase in systolic blood pressure
within each condition over time (Supplementary Fig. 2).
There was a main effect of time on diastolic blood pres-
sure (F(5,1205)= 44.6, p < 0.001, η2= 0.17) and a condi-
tion × time interaction (F(16,1205)= 2.9, p < 0.001, η2=
0.37), indicating an overall increase in diastolic blood
pressure within each condition over time (Supplementary
Fig. 3).
We found a main effect of group on heart rate (F(1,224)
= 15.4, p < 0.001, η2= 0.06) and a main effect of time on
heart rate (F(4,1025)= 188.5, p < 0.001, η2= 0.46). In
addition, we found a group × condition interaction (F
(3,224)= 2.9, p < 0.05, η2= 0.04), indicating increased
heart rate in depressed patients compared with healthy
controls within the fludrocortisone-only condition (Sup-
plementary Fig. 4). Analyses in nonsmokers confirmed
these results.
Mood assessment
We found a main effect of group on current mood state
(F(1,222)= 200.0, p < 0.01, η2= 0.47), indicating that
depressed patients were in a worse mood compared with
healthy controls (Supplementary Fig. 5). However, there
was neither a main effect of condition or time nor a




Fig. 1 Cortisol secretion. Mean cortisol secretion in pg/mL (SE) for a
both groups across conditions, b healthy controls for each condition,




Fig. 2 Aldosterone secretion. Mean aldosterone secretion in pg/mL
(SE) for a both groups across conditions, b healthy controls for each
condition, and c depressed patients for each condition.
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between group × time (F(1,378)= 10.5, p < 0.001, η2=
0.05), indicating that subjective mood ratings of depressed
patients slightly increased during the experiment, while
healthy individuals exhibited a slight decrease in sub-
jective mood (Supplementary Fig. 5).
Cardiovascular risk
Depressed patients and healthy controls did not differ in
blood pressure, heart rate, total cholesterol, LDL choles-
terol, and CRP. However, we found lower HDL choles-
terol and higher glucose levels in depressed patients than
in healthy controls (Table 2). Analyses in the group of
nonsmokers confirmed the results and also showed higher
diastolic blood pressure in depressed patients (M= 80.6,
SD= 7.3) than in healthy controls (M= 77.9, SD= 8.7;
p < 0.05).
Correlational analyses
We calculated correlations between cardiovascular risk
variables and steroid hormone values. To control for
multiple testing, we performed Bonferroni corrections
(p= 0.0018, after 0.05/27). We found a correlation
between cortisol and aldosterone (r= 0.34, p < 0.001), but
no other correlations were significant.
Discussion
The aim of this study was to examine salivary cortisol,
aldosterone, and DHEA-S secretion in depressed patients
and healthy controls after stimulation of MR with flu-
drocortisone and glutamatergic NMDA receptors with
DCS. We also examined CVD risk in these participants.
We report four main results: (1) NMDA receptor stimu-
lation with DCS did not affect steroid hormone secretion
in depressed patients and healthy individuals, (2) MR
stimulation with fludrocortisone inhibited cortisol secre-
tion across groups, (3) depressed patients showed higher
cortisol and aldosterone values, but lower DHEA-S con-
centrations compared with healthy individuals indepen-
dent of condition, and (4) depressed patients had higher
glucose levels and lower HDL cholesterol values than
healthy controls.
There is evidence for a bidirectional association between
glutamate signaling and the HPA axis. For example, stress
and elevated cortisol levels increase glutamate signaling in
the hippocampus and prefrontal cortex3. Conversely, the
NMDA receptor antagonist ketamine activates the HPA
axis and elevates cortisol levels20,21,44,45. However, in this
study, the partial NMDA receptor agonist DCS did not
affect cortisol secretion, which is in line with earlier stu-
dies46–48. Interestingly, a previous study showed that keta-
mine but not memantine (another NMDA receptor
antagonist) increases cortisol secretion44. These findings
suggest that ketamine increases cortisol secretion inde-
pendently of the NMDA receptor. DCS has attracted tre-
mendous interest in neuroscience research because of its
role in learning, neuroplasticity, memory, and as a potential
antidepressant22,49,50. Our results suggest that these effects
are independent of HPA activity.
NMDA receptor stimulation did not affect hormone
secretion, but the MR agonist fludrocortisone inhibited
cortisol (but not aldosterone or DHEA-S) across groups.
It is well known that MR stimulation inhibits HPA
activity51,52. In accordance with our previous findings, the
cortisol responses to fludrocortisone did not differ
between young, unmedicated depressed patients and
healthy individuals in the current study53. This suggests
that MR function is intact in these patients. However,




Fig. 3 DHEA-S secretion. Mean DHEA-S secretion in pg/mL (SE) for a
both groups across conditions, b healthy controls for each condition,
and c depressed patients for each condition.
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of cortisol secretion in patients with psychotic depression.
Furthermore, Juruena et al.13 observed diminished MR
function in patients with treatment-resistant depression.
Given the well-established glucocorticoid resistance in
depressed patients54, the authors speculated that patients
with treatment-resistant depression (and potentially
patients with psychotic depression) are not able to com-
pensate for GR resistance by increasing MR function.
However, our findings suggest that this might be possible
in less severely depressed patients.
The third main result was that depressed patients had
higher cortisol and aldosterone values, but lower DHEA-S
concentrations than healthy individuals. To our knowledge,
this is the first study to demonstrate alterations of three
important steroid hormones in the same patients. Impor-
tantly, all of these hormones are stress responsive27,55 and
have been associated with depression5,30,33,56,57. While
increased cortisol secretion in depressed patients is well
established5,12, only few studies have examined aldosterone
secretion in MDD. However, these studies have consistently
found increased aldosterone levels in depressed patients
compared with healthy individuals30,57. Furthermore, sali-
vary aldosterone was associated with depression severity58
and predicted treatment response to standard anti-
depressants59,60. In turn, patients with primary aldosteron-
ism exhibit more depressive symptoms compared with the
general population61,62. Finally, animal studies demon-
strated that aldosterone increases earlier than corticoster-
one after induction of depressive behavior63 and that
subchronic treatment with aldosterone induces depression-
like behaviors in rats64. In sum, these studies suggest that
aldosterone is closely involved in the pathophysiology
of MDD.
With our cross-sectional design, we cannot determine
causality between depression and altered steroid hormone
secretion. However, there is strong evidence that altera-
tions in steroid hormones contribute to the development
of depression. For example, childhood adversity is asso-
ciated with altered cortisol and DHEA secretion55, which
in turn increases the risk of depression65,66. Furthermore,
aldosterone induces depressive symptoms in animals64,67.
On the other hand, depression itself can alter steroid
hormone concentrations. For example, the lifestyle of
depressed patients (such as poor diet, reduced sleep, and
less physical activity) affects steroid hormone secretion68.
Therefore, the association between depression and altered
steroid secretion is likely bidirectional, leading to a vicious
circle of more severe depression and more profound
disturbances in steroid hormone signaling.
These alterations in steroid hormone secretion likely
contribute to the increased cardiovascular risk in
depressed patients. Indeed, we show in the present study
that depressed patients had higher glucose levels and
lower HDL cholesterol values than healthy controls.
Increased aldosterone is an established risk factor for
mortality in CVD, and blocking MR has beneficial effects
on many CVD endpoints, including mortality69,70. Several
prospective studies in different populations have shown
that higher cortisol values are associated with cardiovas-
cular mortality71–73. In addition, a meta-analysis of
25 studies showed an association between low DHEA-S
levels and increased mortality in patients with CVD29.
Therefore, our findings have strong clinical implications
because they suggest that these endocrine alterations in
depressed patients contribute to their increased CVD risk
and their increased mortality. In our cross-sectional study,
however, there was no correlation between any steroid
hormone and any CVD risk factor. One explanation might
be that we examined a relatively young population of
unmedicated depressed patients and healthy controls,
who did not suffer (yet) from severe metabolic and/or
cardiovascular conditions. Indeed, our participants were
younger and less physically impaired compared with
participants of studies that found an association between
Table 2 Cardiovascular risk in depressed patients and healthy controls.
Healthy controls Depressed patients Statistics
Systolic blood pressure 119.4 (13.2) 119.1 (12.1) t(230)= 0.2, p= 0.87
Diastolic blood pressure 78.4 (8.5) 79.7 (7.2) t(223)=−1.2, p= 0.22
Heart rate 71.6 (10.8) 73.7 (10.0) t(230)=−1.5, p= 0.12
Total cholesterol 181.2 (35.6) 184.6 (39.1) t(229)=−0.7, p= 0.49
HDL cholesterol 69.4 (19.6) 64.1 (17.4) t(229)= 2.1, p= 0.03*
LDL cholesterol 108.0 (33.2) 112.4 (33.3) t(229)=−1.0, p= 0.32
CRP 1.6 (3.6) 1.8 (2.8) t(229)=−0.5, p= 0.59
Glucose 84.2 (14.8) 88.3 (13.1) t(230)=−2.2, p= 0.03*
Values represent mean (SD) and significant differences are marked (*).
HDL cholesterol high-density lipoprotein cholesterol, LDL cholesterol low-density lipoprotein cholesterol, CRP C-reactive protein.
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steroid hormones and CVD74, or an association between
steroid hormones and cardiovascular mortality71–73.
Future longitudinal studies should examine whether
modulating these endocrine systems can improve CVD
risk and psychopathology in depressed patients. Rando-
mized controlled trials have revealed encouraging evi-
dence that DHEA both decreases CVD risk and improves
depressive symptoms75,76.
Our study had several limitations. First, in our sample
there were much more women than men (78% women).
Thus, our results cannot be generalized to men. Fur-
thermore, we studied a comparably young population of
depressed patients with few medical comorbidities, so our
results cannot be generalized to older people and patient
groups with severe medical conditions. However, the
homogeneous nature of our group of depressed patients is
also a strength as it increases internal validity. Second,
there was no specific time of day when we collected the
plasma samples and, therefore, our blood samples were
not restricted to fasting glucose or fasting lipids, but
included non-fasting values as well. However, according
to the consensus statement from the European Athero-
sclerosis Society and European Federation of Clinical
Chemistry and Laboratory Medicine there is no clinically
relevant difference between fasting and non-fasting lipid
measurements77. Furthermore, there is also evidence that
non-fasting glucose values are associated with incident
CVD78,79. Overall, the clinical significance of non-fasting
glucose and non-fasting lipid values seems to be estab-
lished. Third, we did not measure HbA1c as a long-term
marker of glucose concentrations. Fourth, due to the
limited quantity of saliva, we were restricted to three
steroids. Therefore, we chose those steroids for which
several earlier studies had been shown an association with
MDD5,30,33,56,57. The plasma concentrations of the sul-
fated form (DHEA-S) is between 250 and 500 times
higher (women and men, respectively) than the con-
centrations of DHEA80. In addition, both steroid hor-
mones are correlated81,82. Therefore, we believe that
measuring DHEA-S also provides a reliable assessment of
DHEA values. Fifth, we used 250mg of DCS, which is
considered a moderate dosage that can lead to partial
agonism of the NMDA receptor. However, it has been
suggested that DCS acts as an NMDA receptor antagonist
at high doses in the range of 750–1000mg (ref. 17). The
NMDA receptor antagonist ketamine increases cortisol
secretion20,21. However, the NMDA receptor antagonist
memantine does not44. We cannot exclude that a higher
dosage of DCS that acts as an NMDA receptor antagonist
would have affected steroid hormone secretion and fur-
ther studies should examine this question. Sixth, while the
MR affinity of fludrocortisone is ~150 times higher than
its GR affinity83, fludrocortisone has some glucocorticoid
potency. The extent of its glucocorticoid potency ranges
from negligible to rather moderate depending on the
source of the literature and variable being examined84,85.
Thus, remaining GR activity could have contributed to the
effects of fludrocortisone in our study. Finally, even
though we recruited a relatively large sample (n= 232),
we still might have lacked power to find an association
between NMDA receptor stimulation and steroid secre-
tion even though the effect sizes were small and pre-
sumably clinically irrelevant.
Strengths of the study include the lack of antidepressive
treatment during the study, careful matching of healthy
individuals to depressed patients based on age, sex, and
years of education, and strongly controlled experimental
conditions during saliva collection with almost no missing
data. In addition, the demographic characteristics did not
differ between participants across the four conditions,
except for fewer male participants in the fludrocortisone
+DCS condition compared with other conditions. How-
ever, our main findings were independent of condition—
MDD patients showed increased cortisol, increased
aldosterone, and decreased DHEA-S concentrations, and
increased glucose levels and decreased HDL cholesterol
levels compared with controls. Therefore, the differences
in sex distribution across the four conditions likely did not
affect the main results.
In conclusion, we found that steroid hormone altera-
tions and cardiovascular risk are higher in patients with
depression than in healthy individuals. Future research
should prospectively examine whether manipulating these
steroid systems can improve the symptoms and cardio-
vascular risk of patients with depression.
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